Small Cap Feast
Small Cap Feast – 06 February 2020
Set Menu AIM:
Total number of AIM Companies (Incl Susp):
Total number of AIM Companies trading: *
* As at
Set Menu NEX Growth:
Total number of NEX Growth Market Companies (Incl Susp): *
Total number of NEX Growth Market Companies trading: *
* As at
Set Menu Standard List:
Total number of Standard List Companies (Incl Susp): *
Total number of Standard List Companies trading: *
* As at
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
Dish of the Day:
Off the Menu:
What’s Cooking in the IPO Kitchen?
Intention to float by Gemfields Group. No Capital Raise. Currently listed on JSE. (GML:JNB) at circa £122m. The Group’s key producing assets, the Kagem emerald mine in Zambia (believed to be the world’s single largest producing emerald mine) and the Montepuez ruby mine in Mozambique (one of the most significant recently discovered ruby deposits in the world), are both expected to have long mine-lives with potential for expansion. Also owns the Faberge brand. Due Valentines Day 2020.
Main Market (Standard List)
The Proof Of Trust has announced its intention to list on the Standard Market. The Blockchain based business, owns patents to a protocol which facilitates dispute resolution based upon smart contract disputes. Transaction details TBC.
Main Market (Premium)
Ninety One –proposed demerger and public listing of Investec’s global asset management business on LSE and JSE. 30 Sep 2019 AUM £121bn. Sale of existing shares. Expected free float of >60%. Due 16 march.
Cabot Square—Closed ended investment fund focussed on alternative assets and asset manager. Looking to raise £200m. Will target investment opportunities that are expected to generate an attractive risk adjusted return and that can also make a positive ESG impact by focusing on some of the biggest challenges facing societies and economies. Due 14 Feb.
Calisen Group. Potential Intention to Float. Owner and manager of essential energy infrastructure assets through its subsidiaries Calvin Capital and Lowri Beck . Consolidated FY Dec 18 revenue £162.1m and operating profit £25.4m. Raising up to £300m in primary plus partial vendor sale. Expected Admission February 2020
The Global Sustainable Farmland Income Trust will invest in a diversified portfolio of operational farmland assets located in major agricultural markets including the United States, Europe, New Zealand, Australia and certain countries within Latin and South America. Raising up to $300m. Due 28 February.
Investment firm Nippon Active Value fund is seeking to raise up to £200m at an issue price of 100p per share via an IPO. The company aims to invest in a portfolio of quoted Japanese stocks with market capitalisations of up to $1bn. First day of dealings expected early February.
Zapp Scooters, a developer and manufacturer of electric two-wheeled vehicles announced its intention to IPO on the NEX Exchange Growth Market. The Company intends to raise up to £3.5m. Admission is expected to occur on NEX in February 2020.
ImmuPharma (IMM.L) 14.5p £24.2m
Update on activities with Avion Pharmaceuticals LLC following the successful licence and development agreement signed with Avion in November 2019 for the exclusive rights to Lupuzor™ in North America. Key activities completed since November 2019
First joint steering committee (“JSC”) completed in December 2019 to identify and agree the optimised Phase III study design for Lupuzor™ including a focus on those patients presenting with the biomarker anti-dsDNA autoantibody positive
Confirmation that the JSC wish to progress Lupuzor™ into its second international Phase III clinical trial as soon as possible this year
Avion and ImmuPharma to meet with the FDA in Q1 2020 to discuss guidance on a new optimised international Phase III trial protocol
Positive discussions with a number of potential commercial partners of Lupuzor™ outside of the US
Dillistone (DSG.L) 31.5p £6.2m
The supplier of software for the international recruitment industry through Ikiru People, is issued a trading update for the 12 months ended 31 December 2019.
The Board currently expects pre-tax losses before acquisition related items and one off adjustments to be broadly in line with market expectations of a loss of £0.30m (2018: profit £0.02m).
The Company is confident that it will deliver a pre-tax profit prior to exceptional items in both H1 and H2 of 2020. However, the strategic decisions taken mean that this will be delivered on a lower revenue base than previously anticipated, with faster growth than expected from 2021 onwards.
Warpaint (W7L.L) 83p £63.7m
New collaboration with a leading UK supermarket group to sell a core range of over 100 of the Group’s W7 branded products, in over 50 stores across the UK. W7 products will be displayed in bespoke free-standing display units located in the store’s cosmetics aisles.
On FYDec19 trading the Company expects to report revenue of £49.3m and adjusted profit before tax (excluding amortisation in connection with acquisitions, share incentive scheme costs and exceptional items, which the board expects to total approximately £2.8m) of £5.2m for the year ended 31 December 2019, in line with the guidance provided in the Company’s trading update on 20 December 2019.
Kropz (KRPZ.L) 7.5p £21.3m
The emerging African phosphate explorer and developer, advises that, further to the announcement on 18 December 2019, the appeal hearing against Elandsfontein’s valid integrated water use licence (“WUL”) resumed today following a request by the Tribunal for a continuation.
The Company would like to advise the market that, in order to allow the Tribunal the appropriate opportunity to fully review the matter, it will not be providing further comment on the official proceedings until the Tribunal has announced its decision. Three days have been scheduled for the hearing. The timing of the decision is currently unknown.
Pending the Tribunal’s decision, there is no legal impediment to the continuation of the water use activities authorised in the integrated WUL.
Samuel Heath & Sons (HSM.L) 280p £7.1m
Samuel Heath and Sons Plc announces that its Managing Director, David Pick, will be retiring on 31 December 2020. The Board, after careful consideration, has appointed Sales Director, Martyn Whieldon, to the position of Deputy Managing Director with immediate effect for the transitional period, following which he will become Managing Director on Mr Pick’s retirement. A further announcement will be made in due course.
The Company uses its long-established skills and investments in manufacturing metals to produce high-quality products for the bathroom and door hardware markets.
Image Scan Holdings (IGE.L) 2.3p £3.1m
The specialist in the field of real-time X-ray imaging for the security and industrial inspection markets, provides an update ahead of its Annual General Meeting.
- Trading in the year to date has been robust
- Order intake in line with management expectations
- First X-ray images taken with prototype of new Axis X-ray system
- UK distribution agreement signed with Italian X-ray company Gilardoni
- New initiative to develop sales in North America
IGas (IGAS.L) 40.5p £49.5m
Reserves and Trading Update for FY Dec 19. 2P up from 14.56 to 16.05 MMboe .
Significant 2P reserves replacement ~277% (1P ~192%)
- 2P NPV10 of $183m
Net production averaged 2,325 boepd for the year, within guidance, while operating costs for the year were c. $30/boe (at an average 2019 exchange rate of £1:$1.28). IGAS anticipates net production of between 2,250 – 2,450 boepd and operating costs of c.$30/boe (assuming an exchange rate of £1:$1.30) in 2020.
Waterflood Projects remain on track both in terms of delivery and budget, and are expected to be online in H1
The Planning Inspector has now submitted his recommendation report on the Ellesmere Port Appeal to the Secretary of State. A decision is expected on or before 8 April 2020. Free cash flow £15.5m. $40m Reserve Base Loan agreed in October 2019
Touchstone Exploration (TXP.L) 40.75p £65.5m
Flowback testing of the first stage of the Cascadura-1ST1 well has been completed, confirming that the well is a significant liquids rich natural gas discovery.
Stage 1 testing the lower most 162 feet of a total of 777 feet of identified pay in the Herrera formation.
- Average flowback rate during the final 14-hour test period was 5,180 barrels of oil equivalent per day (“boe/d”), including 26.9 million cubic feet per day (“MMcf/d”) of natural gas and 694 barrels per day (“bbls/d”) of natural gas liquids.
- Peak flowback rate of 5,736 boe/d, including 30.2 MMcf/d of natural gas and 710 bbls/d of natural gas liquids.
“The well is expected to be shut-in for a two-week pressure build-up test, following which we anticipate completing and testing an additional 450 feet of identified pay.”
Zegona (ZEG.L) 110p £243m
Zegona announced the payment of an interim dividend of 2.0 pence per share, in line with its dividend policy. In total 4.5 pence per share has been paid to shareholders in the last 12 months, equating to a dividend yield of 4.1%. Zegona has been consistent in its commitment to paying dividends, with more than £35m being paid to shareholders since 2016. Zegona’s policy is to pass 100% of all Euskaltel dividends straight through to its shareholders. Euskaltel S.A. has a strong history of paying dividends, with €55.4m being paid to shareholders in 2019, a 12% increase on the €49.7m paid in 2018. On 5th February 2020, Euskaltel paid an interim dividend to shareholders of €25.0m.
7digital Group (7DIG.L) 0.435p £10.7m
The specialist in B2B end-to-end digital music solutions, announces the appointment of Helen Gilder as an Independent Non-executive Director of the Company with immediate effect.
Helen brings significant technology and financial experience to the Board, with a strong track record as a finance director of fast-growth digital and software companies as well as extensive non-executive experience in the technology and retail sectors.
Helen joined ZOO Digital Group plc in 2000 and was CFO from 2006 to 2018, guiding the business through both its initial AIM IPO and subsequent reverse takeover and re-admission, as well as several secondary fundraisings.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.